Ticker

Analyst Price Targets — CBLL

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
May 12, 2026 10:35 amWilliam PlovanicCanaccord Genuity$25.00$20.06TheFly Ceribell price target lowered to $25 from $28 at Canaccord
December 15, 2025 10:54 amMarie ThibaultBTIG$30.00$20.95StreetInsider BTIG Reiterates Buy Rating on Ceribell (CBLL)
November 5, 2024 10:10 amWilliam PlovanicCanaccord Genuity$30.00$27.26StreetInsider Canaccord Genuity Starts Ceribell (CBLL) at Buy

Latest News for CBLL

Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes

Study published in leading critical care journal shows that higher AI-detected seizure burden is associated with increased odds of disability, further demonstrating the utility of the Ceribell System as a clinical decision-making tool Study published in leading critical care journal shows that higher AI-detected seizure burden is associated with increased odds of disability, further demonstrating the utility of the…

GlobeNewsWire • Jun 8, 2026
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference

SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 46th Annual Growth Stock Conference in Chicago. The presentation will take place on…

GlobeNewsWire • May 20, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for CBLL.

No House trades found for CBLL.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top